Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies.

Friedman J, Morisada M, Sun L, Moore EC, Padget M, Hodge JW, Schlom J, Gameiro SR, Allen CT.

J Immunother Cancer. 2018 Jun 21;6(1):59. doi: 10.1186/s40425-018-0374-2.

2.

PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation.

Morisada M, Clavijo PE, Moore E, Sun L, Chamberlin M, Van Waes C, Hodge JW, Mitchell JB, Friedman J, Allen CT.

Oncoimmunology. 2017 Nov 27;7(3):e1395996. doi: 10.1080/2162402X.2017.1395996. eCollection 2018.

PMID:
29399393
3.

An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppression.

Fujii R, Jochems C, Tritsch SR, Wong HC, Schlom J, Hodge JW.

Cancer Immunol Immunother. 2018 Apr;67(4):675-689. doi: 10.1007/s00262-018-2121-4. Epub 2018 Feb 1.

PMID:
29392336
4.

Combination therapy with an OX40L fusion protein and a vaccine targeting the transcription factor twist inhibits metastasis in a murine model of breast cancer.

Malamas AS, Hammond SA, Schlom J, Hodge JW.

Oncotarget. 2017 Aug 5;8(53):90825-90841. doi: 10.18632/oncotarget.19967. eCollection 2017 Oct 31.

5.

A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.

Fujii R, Schlom J, Hodge JW.

J Neurosurg. 2018 May;128(5):1419-1427. doi: 10.3171/2017.1.JNS162610. Epub 2017 Jul 28.

PMID:
28753113
6.

Dose-dependent enhancement of T-lymphocyte priming and CTL lysis following ionizing radiation in an engineered model of oral cancer.

Morisada M, Moore EC, Hodge R, Friedman J, Cash HA, Hodge JW, Mitchell JB, Allen CT.

Oral Oncol. 2017 Aug;71:87-94. doi: 10.1016/j.oraloncology.2017.06.005. Epub 2017 Jun 10.

PMID:
28688697
7.

ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody.

Jochems C, Hodge JW, Fantini M, Tsang KY, Vandeveer AJ, Gulley JL, Schlom J.

Int J Cancer. 2017 Aug 1;141(3):583-593. doi: 10.1002/ijc.30767. Epub 2017 May 19.

PMID:
28477372
8.

House staff communication training and patient experience scores.

Oladeru OA, Hamadu M, Cleary PD, Hittelman AB, Bulsara KR, Laurans MS, DiCapua DB, Marcolini EG, Moeller JJ, Khokhar B, Hodge JW, Fortin AH, Hafler JP, Bennick MC, Hwang DY.

J Patient Exp. 2017 Mar 1;4(1):28-36. doi: 10.1177/2374373517694533. Epub 2017 Feb 20.

9.

Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7.

Tsang KY, Fantini M, Fernando RI, Palena C, David JM, Hodge JW, Gabitzsch ES, Jones FR, Schlom J.

Vaccine. 2017 May 2;35(19):2605-2611. doi: 10.1016/j.vaccine.2017.03.025. Epub 2017 Apr 4.

10.

Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.

Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S.

Cancer. 2017 Apr 1;123(7):1259-1271. doi: 10.1002/cncr.30449. Epub 2016 Dec 1.

11.
12.

An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele.

Jochems C, Hodge JW, Fantini M, Fujii R, Morillon YM 2nd, Greiner JW, Padget MR, Tritsch SR, Tsang KY, Campbell KS, Klingemann H, Boissel L, Rabizadeh S, Soon-Shiong P, Schlom J.

Oncotarget. 2016 Dec 27;7(52):86359-86373. doi: 10.18632/oncotarget.13411.

13.

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells.

Jochems C, Fantini M, Fernando RI, Kwilas AR, Donahue RN, Lepone LM, Grenga I, Kim YS, Brechbiel MW, Gulley JL, Madan RA, Heery CR, Hodge JW, Newton R, Schlom J, Tsang KY.

Oncotarget. 2016 Jun 21;7(25):37762-37772. doi: 10.18632/oncotarget.9326.

14.

Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody.

Nagaya T, Nakamura Y, Sato K, Harada T, Choyke PL, Hodge JW, Schlom J, Kobayashi H.

Oncotarget. 2017 Jan 31;8(5):8807-8817. doi: 10.18632/oncotarget.12410.

15.

Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab.

Fujii R, Friedman ER, Richards J, Tsang KY, Heery CR, Schlom J, Hodge JW.

Oncotarget. 2016 Jun 7;7(23):33498-511. doi: 10.18632/oncotarget.9256.

16.

Tumor Cells Surviving Exposure to Proton or Photon Radiation Share a Common Immunogenic Modulation Signature, Rendering Them More Sensitive to T Cell-Mediated Killing.

Gameiro SR, Malamas AS, Bernstein MB, Tsang KY, Vassantachart A, Sahoo N, Tailor R, Pidikiti R, Guha CP, Hahn SM, Krishnan S, Hodge JW.

Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):120-30. doi: 10.1016/j.ijrobp.2016.02.022. Epub 2016 Feb 13.

17.

Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers.

Moore EC, Cash HA, Caruso AM, Uppaluri R, Hodge JW, Van Waes C, Allen CT.

Cancer Immunol Res. 2016 Jul;4(7):611-20. doi: 10.1158/2326-6066.CIR-15-0252. Epub 2016 Apr 13.

18.

Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin.

Kwilas AR, Ardiani A, Gameiro SR, Richards J, Hall AB, Hodge JW.

Oncotarget. 2016 Apr 26;7(17):23498-511. doi: 10.18632/oncotarget.8274.

19.

Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?

Bernstein MB, Krishnan S, Hodge JW, Chang JY.

Nat Rev Clin Oncol. 2016 Aug;13(8):516-24. doi: 10.1038/nrclinonc.2016.30. Epub 2016 Mar 8. Review.

PMID:
26951040
21.

Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.

Gameiro SR, Malamas AS, Tsang KY, Ferrone S, Hodge JW.

Oncotarget. 2016 Feb 16;7(7):7390-402. doi: 10.18632/oncotarget.7180.

22.

Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death.

Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R, Cirone M, Coosemans A, Coulie PG, De Ruysscher D, Dini L, de Witte P, Dudek-Peric AM, Faggioni A, Fucikova J, Gaipl US, Golab J, Gougeon ML, Hamblin MR, Hemminki A, Herrmann M, Hodge JW, Kepp O, Kroemer G, Krysko DV, Land WG, Madeo F, Manfredi AA, Mattarollo SR, Maueroder C, Merendino N, Multhoff G, Pabst T, Ricci JE, Riganti C, Romano E, Rufo N, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Vacchelli E, Vandenabeele P, Vandenberk L, Van den Eynde BJ, Van Gool S, Velotti F, Zitvogel L, Agostinis P.

Front Immunol. 2015 Nov 20;6:588. doi: 10.3389/fimmu.2015.00588. eCollection 2015.

23.

Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack.

Grenga I, Kwilas AR, Donahue RN, Farsaci B, Hodge JW.

J Immunother Cancer. 2015 Nov 17;3:52. doi: 10.1186/s40425-015-0096-7. eCollection 2015.

24.

The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.

Gabitzsch ES, Tsang KY, Palena C, David JM, Fantini M, Kwilas A, Rice AE, Latchman Y, Hodge JW, Gulley JL, Madan RA, Heery CR, Balint JP Jr, Jones FR, Schlom J.

Oncotarget. 2015 Oct 13;6(31):31344-59. doi: 10.18632/oncotarget.5181.

25.

ABO blood type correlates with survival on prostate cancer vaccine therapy.

Muthana SM, Gulley JL, Hodge JW, Schlom J, Gildersleeve JC.

Oncotarget. 2015 Oct 13;6(31):32244-56. doi: 10.18632/oncotarget.4993.

26.
27.

Improving clinical benefit for prostate cancer patients through the combination of androgen deprivation and immunotherapy.

Kwilas AR, Gameiro SR, Kim PS, Malamas AS, Hodge JW.

Oncoimmunology. 2015 Mar 2;4(6):e1009303. eCollection 2015 Jun.

28.

Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy.

Kwilas AR, Donahue RN, Tsang KY, Hodge JW.

Cancer Cell Microenviron. 2015;2(1). pii: e677.

29.

Consensus guidelines for the detection of immunogenic cell death.

Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 13;3(9):e955691. eCollection 2014 Oct. Review.

30.

Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities.

Garnett-Benson C, Hodge JW, Gameiro SR.

Semin Radiat Oncol. 2015 Jan;25(1):46-53. doi: 10.1016/j.semradonc.2014.07.002. Review.

31.
32.
33.

Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens.

Gameiro SR, Ardiani A, Kwilas A, Hodge JW.

Oncoimmunology. 2014 Apr 29;3:e28643. eCollection 2014.

34.

Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.

Farsaci B, Donahue RN, Coplin MA, Grenga I, Lepone LM, Molinolo AA, Hodge JW.

Cancer Immunol Res. 2014 Nov;2(11):1090-102. doi: 10.1158/2326-6066.CIR-14-0076. Epub 2014 Aug 4.

35.

Immunobiology of radiotherapy: new paradigms.

Ahmed MM, Guha C, Hodge JW, Jaffee E.

Radiat Res. 2014 Aug;182(2):123-5. doi: 10.1667/RR13849.1. Epub 2014 Jul 18. No abstract available.

36.

In vivo effects of lattice radiation therapy on local and distant lung cancer: potential role of immunomodulation.

Kanagavelu S, Gupta S, Wu X, Philip S, Wattenberg MM, Hodge JW, Couto MD, Chung KD, Ahmed MM.

Radiat Res. 2014 Aug;182(2):149-62. doi: 10.1667/RR3819.1. Epub 2014 Jul 18.

PMID:
25036982
37.

Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells.

Aryankalayil MJ, Makinde AY, Gameiro SR, Hodge JW, Rivera-Solis PP, Palayoor ST, Ahmed MM, Coleman CN.

Radiat Res. 2014 Aug;182(2):139-48. doi: 10.1667/RR13731.1. Epub 2014 Jul 8.

38.

Unlocking the combination: potentiation of radiation-induced antitumor responses with immunotherapy.

Wattenberg MM, Fahim A, Ahmed MM, Hodge JW.

Radiat Res. 2014 Aug;182(2):126-38. doi: 10.1667/RR13374.1. Epub 2014 Jun 24. Review.

39.

Therapeutic cancer vaccines.

Schlom J, Hodge JW, Palena C, Tsang KY, Jochems C, Greiner JW, Farsaci B, Madan RA, Heery CR, Gulley JL.

Adv Cancer Res. 2014;121:67-124. doi: 10.1016/B978-0-12-800249-0.00002-0. Review.

PMID:
24889529
40.

Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.

Gulley JL, Madan RA, Tsang KY, Jochems C, Marté JL, Farsaci B, Tucker JA, Hodge JW, Liewehr DJ, Steinberg SM, Heery CR, Schlom J.

Cancer Immunol Res. 2014 Feb;2(2):133-41. doi: 10.1158/2326-6066.CIR-13-0108. Epub 2013 Nov 4.

41.

Harnessing the potential of radiation-induced immune modulation for cancer therapy.

Ahmed MM, Hodge JW, Guha C, Bernhard EJ, Vikram B, Coleman CN.

Cancer Immunol Res. 2013 Nov;1(5):280-4. doi: 10.1158/2326-6066.CIR-13-0141. Review.

42.

Humoral response to a viral glycan correlates with survival on PROSTVAC-VF.

Campbell CT, Gulley JL, Oyelaran O, Hodge JW, Schlom J, Gildersleeve JC.

Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):E1749-58. doi: 10.1073/pnas.1314722111. Epub 2014 Apr 14. Erratum in: Proc Natl Acad Sci U S A. 2015 Jun 30;112(26):E3451.

43.

A pan inhibitor of DASH family enzymes induces immunogenic modulation and sensitizes murine and human carcinoma cells to antigen-specific cytotoxic T lymphocyte killing: implications for combination therapy with cancer vaccines.

Donahue RN, Duncan BB, Fry TJ, Jones B, Bachovchin WW, Kiritsy CP, Lai JH, Wu W, Zhao P, Liu Y, Tsang KY, Hodge JW.

Vaccine. 2014 May 30;32(26):3223-31. doi: 10.1016/j.vaccine.2014.04.008. Epub 2014 Apr 13.

44.

Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions.

Bernstein MB, Garnett CT, Zhang H, Velcich A, Wattenberg MM, Gameiro SR, Kalnicki S, Hodge JW, Guha C.

Cancer Biother Radiopharm. 2014 May;29(4):153-61. doi: 10.1089/cbr.2013.1578. Epub 2014 Apr 2.

45.

Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets.

Wattenberg MM, Kwilas AR, Gameiro SR, Dicker AP, Hodge JW.

Br J Cancer. 2014 Mar 18;110(6):1472-80. doi: 10.1038/bjc.2014.79. Epub 2014 Feb 20.

46.

Vaccine-mediated immunotherapy directed against a transcription factor driving the metastatic process.

Ardiani A, Gameiro SR, Palena C, Hamilton DH, Kwilas A, King TH, Schlom J, Hodge JW.

Cancer Res. 2014 Apr 1;74(7):1945-57. doi: 10.1158/0008-5472.CAN-13-2045. Epub 2014 Feb 11.

47.

Attacking malignant cells that survive therapy: Exploiting immunogenic modulation.

Hodge JW, Kwilas A, Ardiani A, Gameiro SR.

Oncoimmunology. 2013 Dec 1;2(12):e26937. Epub 2013 Nov 6.

48.

Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing.

Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW.

Oncotarget. 2014 Jan 30;5(2):403-16.

49.

Prostate-specific antigen bounce predicts for a favorable prognosis following brachytherapy: a meta-analysis.

Bernstein MB, Ohri N, Hodge JW, Garg M, Bodner W, Kalnicki S, Dicker AP, Guha C.

J Contemp Brachytherapy. 2013 Dec;5(4):210-4. doi: 10.5114/jcb.2013.38875. Epub 2013 Nov 14.

50.

Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine.

Hamilton DH, Litzinger MT, Jales A, Huang B, Fernando RI, Hodge JW, Ardiani A, Apelian D, Schlom J, Palena C.

Oncotarget. 2013 Oct;4(10):1777-90.

Supplemental Content

Loading ...
Support Center